NABP Compounding Pharmacy Accreditation Consulting
For 503A Compounding Pharmacies and 503B Outsourcing Facilities Seeking National Quality Credentials
What Is NABP Compounding Pharmacy Accreditation?
NABP Compounding Pharmacy Accreditation is a voluntary national accreditation program for compounding pharmacies — both traditional patient-specific 503A compounders and FDA-registered 503B outsourcing facilities — that wish to demonstrate alignment with USP compounding standards, compliance with applicable federal and state laws, and commitment to patient safety in the preparation of compounded medications. The accreditation validates that a compounding pharmacy operates under rigorously documented quality systems, maintains appropriate facility standards, and has demonstrated personnel competency in compounding practice.
Compounding pharmacy operates in a complex regulatory environment defined by the intersection of state pharmacy law, FDA oversight under the Drug Quality and Security Act (DQSA), and USP standards. NABP Compounding Pharmacy Accreditation provides a nationally recognized quality credential that demonstrates compliance across this multi-layered framework. For compounding pharmacies seeking to expand their patient or prescriber base, participate in payer programs, or demonstrate quality to health system clients, accreditation is an increasingly important market differentiator.
Who Pursues NABP Compounding Pharmacy Accreditation?
NABP Compounding Pharmacy Accreditation is available to any pharmacy that compounds medications. Primary applicant types include:
- 503A compounding pharmacies — traditional compounding pharmacies that prepare patient-specific compounds pursuant to valid prescriptions for individual patients
- 503B outsourcing facilities — FDA-registered facilities that may compound without patient-specific prescriptions for hospitals and other healthcare facilities, subject to FDA's Current Good Manufacturing Practice (CGMP) requirements
- Sterile compounding pharmacies — pharmacies that prepare sterile parenteral, ophthalmic, or other sterile preparations subject to USP Chapter 797
- Non-sterile compounding pharmacies — pharmacies that prepare topical, oral, or other non-sterile compounds subject to USP Chapter 795
- Hazardous drug compounders — pharmacies that handle antineoplastic and other hazardous drugs in compounding, subject to USP Chapter 800
- Compounding pharmacies serving specialty markets — pharmacies serving veterinary, pediatric, pain management, or hormone therapy markets who want accreditation to support prescriber and patient confidence
The Regulatory Landscape for Compounding Pharmacies
Compounding pharmacies operate under a layered regulatory framework that creates significant compliance complexity:
FDA and the DQSA (503A vs. 503B)
The Drug Quality and Security Act (DQSA) of 2013 established two pathways for compounding under federal law. Section 503A governs traditional compounding pharmacies that prepare patient-specific compounds pursuant to valid prescriptions — these pharmacies operate primarily under state pharmacy law with FDA authority to act on certain safety grounds. Section 503B governs outsourcing facilities that register with FDA, comply with CGMP requirements, and may compound without patient-specific prescriptions for hospitals and healthcare facilities. The regulatory burden, inspection regime, and quality standards applicable to 503A and 503B entities differ substantially. NABP Compounding Pharmacy Accreditation covers both pathways, with standards calibrated to the applicable regulatory framework.
USP Compounding Standards
USP standards govern the quality of compounded preparations across all compounding practice settings:
- USP Chapter 795 — Non-Sterile Preparations: covers formulation, beyond-use dating, quality controls, and environmental requirements for non-sterile compounding
- USP Chapter 797 — Sterile Preparations: covers clean room design, ISO classification, environmental monitoring, personnel training and competency, beyond-use dating, quality control testing, and documentation for sterile compounding. USP 797 was substantially revised with new requirements fully effective in 2023.
- USP Chapter 800 — Hazardous Drugs: covers facilities, equipment, PPE, work practices, and documentation for compounding with hazardous drugs. Applies to any pharmacy handling hazardous drug compounds.
NABP Compounding Pharmacy Accreditation requires alignment with the applicable USP chapters based on the types of compounding the pharmacy performs. Compliance is evaluated through documentation review and, in some cases, facility inspection.
Bulk Drug Substances
Both 503A and 503B compounders face evolving FDA requirements governing which bulk drug substances can be used in compounding. Under Section 503A, compounders can use bulk substances included in the USP or NF monograph or on FDA's 503A bulk list. Under Section 503B, bulk substances can only be used if the compound is on FDA's drug shortage list or on FDA's 503B bulk list. IHS stays current on FDA's evolving bulk drug substance lists and advises clients on compliance with these requirements as part of every compounding accreditation engagement.
NABP Compounding Pharmacy Accreditation Requirements
Prerequisite: VPP Inspection
A key requirement for NABP Compounding Pharmacy Accreditation is completing a prerequisite Verified Pharmacy Program (VPP) inspection within 6 months of the application date. The VPP inspection is an on-site facility inspection conducted by NABP-trained inspectors that evaluates the pharmacy's physical operations against applicable standards. The VPP inspection is a separate process from the accreditation documentation review and must be completed before accreditation can be granted.
USP Compliance Documentation
The pharmacy must demonstrate compliance with all applicable USP chapters through documented policies, procedures, environmental monitoring data, personnel competency records, quality control testing results, and beyond-use dating policies. The depth of documentation required varies by compounding type — sterile compounding under USP 797 requires significantly more documentation than non-sterile compounding under USP 795.
Personnel Competency
All pharmacists and pharmacy technicians involved in compounding must demonstrate documented competency in the specific compounding techniques they perform. For sterile compounding, this includes media fill testing, gloved fingertip sampling, and garbing competency assessments. Personnel competency must be re-evaluated at defined intervals and whenever new compounding techniques or products are introduced.
Quality Assurance and CAPA
The pharmacy must maintain a quality assurance program that monitors compounding quality indicators — including beyond-use dating compliance, environmental monitoring results, patient complaint tracking, and compounding error rates. Corrective and preventive action (CAPA) processes must be documented for all quality events. Annual quality reviews are required.
Facility and Equipment
The compounding facility must meet the physical requirements of applicable USP chapters, including cleanroom ISO classification (for sterile compounding), equipment calibration and maintenance, and segregated compounding areas for hazardous drugs. Facility qualification documentation must be current.
How IHS Supports Compounding Pharmacy Accreditation
Thomas G. Goddard, JD, PhD — IHS's principal consultant and former Chief Operating Officer and General Counsel of URAC — leads every compounding pharmacy accreditation engagement with direct attention to the specific compounding types performed, applicable USP standards, and FDA regulatory posture of the pharmacy.
Regulatory Framework Assessment
IHS begins by mapping the pharmacy's compounding activities against the applicable regulatory framework — 503A vs. 503B, applicable USP chapters, state compounding law, and FDA enforcement activity relevant to the pharmacy's compound categories. This framework assessment ensures the engagement is scoped correctly from the outset.
USP Compliance Gap Assessment
IHS conducts a detailed gap assessment against the applicable USP chapters, reviewing environmental monitoring data, beyond-use dating policies, personnel competency records, facility qualification documentation, and CAPA records. For sterile compounders, the USP 797 assessment is typically the most extensive component of the engagement.
VPP Inspection Preparation
IHS prepares the pharmacy for the prerequisite VPP inspection through a mock walkthrough that replicates the inspection process, identifies remaining gaps, and ensures the pharmacy's operations team is ready to demonstrate competency to NABP inspectors.
Documentation Development and Application Support
IHS develops or revises the full documentation infrastructure required for accreditation and prepares the accreditation application package. Post-VPP inspection corrective action support is provided if needed.
Ready to Pursue Compounding Pharmacy Accreditation?
Whether you are a 503A compounder seeking national quality credentials or a 503B outsourcing facility building your quality infrastructure, IHS provides the structured consulting expertise to achieve NABP Compounding Pharmacy Accreditation.
Schedule a Free Discovery Session